DEFA1 · Western blot design guide

DEFA1 Western Blot Planning Guide

Plan a DEFA1 Western blot around the catalog-observed 10.2 kDa band, image-backed A10546 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for DEFA1 (DEFA1): expected band 10.2 kDa, antibody A10546, and guide-derived SDS-PAGE protocol steps
DEFA1 Western blot protocol sheet — expected band 10.2 kDa, antibody A10546, controls and PMC citations. Open the full DEFA1 WB guide →

DEFA1 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 10.2 kDa
Observed band Not reported — verify product WB image
Gel 15%
Positive control ⓘ Spleen
Negative control ⓘ Appendix
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 10.2 kDa
ⓘ Localization Secreted
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Rat
Section 1

Real Curated DEFA1 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateBone marrow
Gel %15%
Load20-30 µg total protein per lane
TransferSemi-dry, short transfer
Membrane0.2 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA10546 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected DEFA1 Western Blot Band Size?

Use the product-observed 10.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
10.2 kDaMatches the authoritative product WB observation.
10.2 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected DEFA1 appearancePlan around 10.2 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band10.2 kDa; use this as the primary experimental expectation.
Calculated mass10.2 kDa from UniProt P59665; retain as context.
Gel selection15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A10546.
Why is my band missing or off?
SituationLikely causeNext action
10.2 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for DEFA1 Western blot

🧪Use Spleen as the first positive-control candidate and Appendix as the HPA Not detected negative candidate.
Positive control: Spleen (High)
Negative control: Appendix (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for DEFA1

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Spleen Reported tissue cells High Protein (HPA) HPA →
Bone marrow Reported tissue cells High Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Appendix Reported tissue cells Not detected Protein (HPA) HPA →
Breast Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced DEFA1 Western Blot Tips

Deeper troubleshooting and optimisation questions for DEFA1, answered from its protein features.

Which band should guide the blot?
Use 10.2 kDa, the observation attached to the authoritative A10546 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 10.2 kDa expectation.
Which positive control should I start with?
Start with Spleen, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Appendix as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for DEFA1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A10546 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

DEFA1 Western Blot Reagents

Human/Rat-reactive DEFA1 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for DEFA1 using A10546; observed band 10.2 kDa
Anti-Alpha Defensin 1/DEFA1 Antibody Picoband®
Cat # A10546

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P59665
  2. Human Protein Atlas — DEFA1
  3. A10546 product record
  4. PMC12652293 — Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma (International journal of molecular sciences, 2025)
  5. PMC3069341 — An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer (Molecular & cellular proteomics : MCP, 2011)
  6. PMC11880931 — DEFA1, Primarily Expressed at the Invasive Tumor Front, Promotes OSCC Cell Invasion and Tumor Growth (Cancer genomics & proteomics, 2025)